Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Travere TherapeuticsAmneal PharmaceuticalsOlema PharmaceuticalsZealand Pharma A/SIronwood Pharmaceuticals
SymbolNASDAQ:TVTXNYSE:AMRXNASDAQ:OLMANASDAQ:ZEALNASDAQ:IRWD
Price Information
Current Price$24.95$5.89$36.14$32.56$10.61
52 Week RangeBuyBuyBuyBuyHold
MarketRank™
Overall Score1.21.81.61.21.6
Analysis Score3.52.43.53.51.1
Community Score2.62.24.32.52.2
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.00.01.7
Earnings & Valuation Score0.04.40.00.03.1
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyHold
Consensus Price Target$44.33$7.00$60.67$43.00$11.40
% Upside from Price Target77.69% upside18.85% upside67.87% upside32.06% upside7.45% upside
Trade Information
Market Cap$1.51 billion$1.77 billion$1.45 billion$1.41 billion$1.71 billion
Beta0.771.27N/A1.191.46
Average Volume598,8721,990,179149,10514,2162,143,958
Sales & Book Value
Annual Revenue$175.34 million$1.63 billionN/A$6.20 million$428.41 million
Price / Sales8.601.09N/A227.923.99
CashflowN/A$1.37 per shareN/AN/A$0.54 per share
Price / CashN/A4.29N/AN/A19.49
Book Value$5.15 per share$1.16 per shareN/A$5.85 per share($0.59) per share
Price / Book4.845.08N/A5.57-17.98
Profitability
Net Income$-146,430,000.00$-361,920,000.00N/A$-85,670,000.00$21.50 million
EPS($3.46)$0.27N/A($2.54)$0.55
Trailing P/E RatioN/A14.370.00N/A15.38
Forward P/E RatioN/A8.92N/AN/A9.23
P/E GrowthN/A0.29N/AN/AN/A
Net Margins-40.24%3.30%N/A-214.31%27.77%
Return on Equity (ROE)-29.27%42.02%N/A-38.34%-240.80%
Return on Assets (ROA)-12.25%3.82%N/A-30.40%27.05%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.71%8.20%N/AN/A71.91%
Current Ratio6.60%2.31%N/A6.76%13.17%
Quick Ratio6.50%1.60%N/A6.51%13.17%
Ownership Information
Institutional Ownership PercentageN/A33.49%N/A4.32%N/A
Insider Ownership Percentage4.63%26.32%N/AN/A2.40%
Miscellaneous
EmployeesN/A6,00036329232
Shares Outstanding60.44 million299.82 million40.17 million43.40 million160.96 million
Next Earnings Date5/10/2021 (Estimated)5/7/2021 (Confirmed)6/16/2021 (Estimated)5/13/2021 (Estimated)5/5/2021 (Estimated)
OptionableOptionableOptionableNot OptionableNot OptionableOptionable
SourceHeadline
If You Like EPS Growth Then Check Out Ironwood Pharmaceuticals (NASDAQ:IRWD) Before Its Too LateIf You Like EPS Growth Then Check Out Ironwood Pharmaceuticals (NASDAQ:IRWD) Before It's Too Late
finance.yahoo.com - April 15 at 2:43 PM
Ironwood Pharmaceuticals (IRWD) Shares Cross Below 200 DMAIronwood Pharmaceuticals (IRWD) Shares Cross Below 200 DMA
nasdaq.com - April 7 at 6:24 PM
First Week of November 19th Options Trading For Ironwood Pharmaceuticals (IRWD)First Week of November 19th Options Trading For Ironwood Pharmaceuticals (IRWD)
nasdaq.com - March 19 at 3:28 PM
Ironwood (IRWD) Up 20.4% Since Last Earnings Report: Can It Continue?Ironwood (IRWD) Up 20.4% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - March 19 at 3:28 PM
IRWD Makes Bullish Cross Above Critical Moving AverageIRWD Makes Bullish Cross Above Critical Moving Average
nasdaq.com - March 8 at 12:53 PM
Edward Owens Is The Independent Director of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) And They Just Picked Up 5.9% More SharesEdward Owens Is The Independent Director of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) And They Just Picked Up 5.9% More Shares
finance.yahoo.com - March 1 at 1:27 PM
Ironwood Pharmaceuticals to Present at Upcoming Investor ConferencesIronwood Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - February 19 at 5:31 PM
Ironwood Pharmaceuticals, Inc.s (IRWD) CEO Mark Mallon on Q4 2020 Results - Earnings Call TranscriptIronwood Pharmaceuticals, Inc.'s (IRWD) CEO Mark Mallon on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 19 at 12:30 PM
Ironwood Pharmaceuticals is Now Oversold (IRWD)Ironwood Pharmaceuticals is Now Oversold (IRWD)
nasdaq.com - February 18 at 8:22 PM
Ironwood Pharmaceuticals (IRWD) Surpasses Q4 Earnings and Revenue EstimatesIronwood Pharmaceuticals (IRWD) Surpasses Q4 Earnings and Revenue Estimates
msn.com - February 17 at 1:30 PM
Recap: Ironwood Pharmaceuticals Q4 EarningsRecap: Ironwood Pharmaceuticals Q4 Earnings
finance.yahoo.com - February 17 at 1:30 PM
Ironwood Pharmaceuticals Inc (IRWD) Q4 2020 Earnings Call TranscriptIronwood Pharmaceuticals Inc (IRWD) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 17 at 1:30 PM
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full YearIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year
us.acrofan.com - February 17 at 8:30 AM
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial GuidanceIronwood Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results, Exceeding or Meeting Full Year 2020 Financial Guidance; Provides Full Year 2021 Financial Guidance
finance.yahoo.com - February 17 at 8:30 AM
Ironwood Pharmaceuticals Q4 2020 Earnings PreviewIronwood Pharmaceuticals Q4 2020 Earnings Preview
seekingalpha.com - February 16 at 12:40 PM
Ironwood CEO Steps Down Months After Clinical Trial Failure, Names Thomas McCourt As Interim Chief ExecutiveIronwood CEO Steps Down Months After Clinical Trial Failure, Names Thomas McCourt As Interim Chief Executive
feeds.benzinga.com - February 9 at 5:29 AM
Ironwood Pharmaceuticals Announces CEO TransitionIronwood Pharmaceuticals Announces CEO Transition
finance.yahoo.com - February 8 at 6:04 PM
Investors Arent Entirely Convinced About Ironwood Pharmaceuticals, Inc.s (NASDAQ:IRWD) EarningsInvestors Aren't Entirely Convinced About Ironwood Pharmaceuticals, Inc.'s (NASDAQ:IRWD) Earnings
finance.yahoo.com - February 8 at 1:03 PM
Ironwood PharmaceuticalsIronwood Pharmaceuticals
fool.com - February 6 at 6:25 PM
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update CallIronwood Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Investor Update Call
finance.yahoo.com - February 3 at 8:01 PM
IRWD Crosses Below Key Moving Average LevelIRWD Crosses Below Key Moving Average Level
nasdaq.com - January 23 at 6:44 PM
Interesting IRWD Put And Call Options For March 19thInteresting IRWD Put And Call Options For March 19th
nasdaq.com - January 15 at 12:47 PM
Ironwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare ConferenceIronwood Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 8:10 AM
Ironwood (IRWD) Up 19.7% Since Last Earnings Report: Can It Continue?Ironwood (IRWD) Up 19.7% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - December 5 at 4:33 PM
Ironwood Pharmaceuticals Appoints Jay P. Shepard to Board of DirectorsIronwood Pharmaceuticals Appoints Jay P. Shepard to Board of Directors
finance.yahoo.com - December 3 at 1:19 PM
DateCompanyBrokerageAction
4/12/2021Travere TherapeuticsWedbushLower Price Target
3/3/2021Travere TherapeuticsSVB LeerinkReiterated Rating
3/2/2021Travere TherapeuticsBMO Capital MarketsLower Price Target
2/3/2021Travere TherapeuticsCanaccord GenuityBoost Price Target
11/23/2020Travere TherapeuticsEvercore ISIInitiated Coverage
4/14/2021Amneal PharmaceuticalsGuggenheimBoost Price Target
3/19/2021Amneal PharmaceuticalsPiper SandlerBoost Price Target
3/15/2021Amneal PharmaceuticalsThe Goldman Sachs GroupUpgrade
3/1/2021Amneal PharmaceuticalsBarclaysBoost Price Target
5/13/2020Amneal PharmaceuticalsSunTrust BanksBoost Price Target
4/16/2020Amneal PharmaceuticalsRoyal Bank of CanadaReiterated Rating
4/2/2020Amneal PharmaceuticalsMorgan StanleyLower Price Target
12/13/2019Amneal PharmaceuticalsPiper Jaffray CompaniesBoost Price Target
12/12/2019Amneal PharmaceuticalsBTIG ResearchBoost Price Target
12/12/2019Amneal PharmaceuticalsRaymond JamesDowngrade
11/12/2019Amneal PharmaceuticalsJPMorgan Chase & Co.Downgrade
12/14/2020Olema PharmaceuticalsJefferies Financial GroupInitiated Coverage
12/14/2020Olema PharmaceuticalsCowenInitiated Coverage
8/13/2020Zealand Pharma A/SNeedham & Company LLCInitiated Coverage
11/6/2020Ironwood PharmaceuticalsCredit Suisse GroupBoost Price Target
9/30/2020Ironwood PharmaceuticalsWells Fargo & CompanyDowngrade
8/3/2020Ironwood PharmaceuticalsNorthland SecuritiesReiterated Rating
5/11/2020Ironwood PharmaceuticalsHC WainwrightLower Price Target
5/2/2019Ironwood PharmaceuticalsMizuhoSet Price Target
(Data available from 4/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.